CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference

Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) has announced participation in the 22nd Annual Needham Healthcare Conference, taking place virtually from April 17-20, 2023. The company's CEO, Sam Kulkarni, will present during a fireside chat on April 19, 2023, at 3:00 p.m. ET. The session will be accessible via a live webcast on the company's Investors page, and will be available for replay for 14 days post-event. CRISPR Therapeutics is recognized for its innovative approach in gene editing, leveraging the CRISPR/Cas9 technology to develop treatments for various serious diseases, including hemoglobinopathies, oncology, and rare diseases, in collaboration with partners like Bayer and Vertex Pharmaceuticals.

ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 22^nd Annual Needham Healthcare Conference being held virtually from April 17^th- 20^th, 2023.

Fireside Chat
Presenter: Sam Kulkarni, Chief Executive Officer
Date: Wednesday, April 19, 2023
Time: 3:00 p.m. ET

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com

FAQ

What is the date and time of the CRISPR Therapeutics fireside chat?

The fireside chat is scheduled for April 19, 2023, at 3:00 p.m. ET.

Who will present at the CRISPR Therapeutics fireside chat?

Sam Kulkarni, the CEO of CRISPR Therapeutics, will present at the fireside chat.

How can I watch the CRISPR Therapeutics fireside chat?

The fireside chat will be available via a live webcast on the company's Investors page.

What is CRISPR Therapeutics known for?

CRISPR Therapeutics is known for developing gene-based medicines using CRISPR/Cas9 technology.

Which diseases does CRISPR Therapeutics aim to treat?

CRISPR Therapeutics targets diseases such as hemoglobinopathies, oncology, and rare diseases.